文献速递前列腺癌

主动监测中止原因:Movember GAP3联盟12国21中心评估

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
PubMed 文献 · Eur Urol · 2018-10-29

基于Movember GAP3数据库10296例接受主动监测的前列腺癌男性,评估5年随访中主动监测的中止原因。5年累积进展发生率为27.5%(95%CI 26.4-28.6%),10年为38.2%(95%CI 36.7-39.9%);5年内43.6%男性退出主动监测,主要因疾病进展征象。需改进主动监测的选择工具以正确分配患者。

要点

  • 5年主动监测退出率为43.6%,主要原因为疾病进展征象。
  • 5年累积进展发生率为27.5%,10年升至38.2%。
  • 12.8%男性无进展证据即转为积极治疗,提示选择工具需改进。

核心结论

  • 全球主动监测实践中,5年随访内43.6%男性退出主动监测,主要因疾病进展征象。
  • 需改进主动监测选择工具以正确分配前列腺癌患者,减少无进展证据的转换治疗。

研究设计与样本

  • 基于Movember GAP3数据库,比较12国21中心10296例接受主动监测的前列腺癌男性数据。
  • 采用累积发生率方法估计主动监测中止的累积发生率率。

主要发现

  • 5年随访中27.5%(95%CI 26.4-28.6%)男性出现疾病进展征象。
  • 12.8%(95%CI 12.0-13.6%)无进展证据转为积极治疗,1.7%(95%CI 1.5-2.0%)继续观察等待。
  • 1.7%(95%CI 1.4-2.1%)死于其他原因。
  • 5年累积进展发生率为27.5%(95%CI 26.4-28.6%),10年为38.2%(95%CI 36.7-39.9%)。

临床怎么用

  • 临床应关注主动监测退出原因,区分疾病进展与无进展证据的转换治疗。
  • 改进选择工具以优化前列腺癌患者主动监测的分配,减少不必要退出。

局限性

  • 因中止原因信息有限和随访有限,并非所有中心纳入分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). OBJECTIVE: Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. DESIGN, SETTING, AND PARTICIPANTS: We compared data from 10296 men on AS from 21 centres across 12 countries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. RESULTS AND LIMITATIONS: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for <5yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4-28.6%) at 5yr and 38.2% (95% CI: 36.7-39.9%) at 10yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. CONCLUSIONS: Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. PATIENT SUMMARY: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Van Hemelrijck M, Ji X, Helleman J, et al. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. Eur Urol. 2018. PMID: 30385049. doi:10.1016/j.eururo.2018.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。